-+ 0.00%
-+ 0.00%
-+ 0.00%

Syndax Pharmaceuticals Reports Q2 2025 Net Loss of $71.8M, EPS of $0.83; Revuforj Sales Surge 43% Over Q1 2025

Reuters·08/04/2025 20:01:25

Please log in to view news